Navigation Links
AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial,with Alkaline Phosphatase in Acute Renal Failure

Results expand potential application of key product in AM-Pharma's pipeline

BUNNIK, The Netherlands, 14 March, 2007. AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to treat infectious and inflammatory diseases, today announced positive results in patients with Acute Renal Failure. The patients involved were a subgroup of a Phase IIa trial with Alkaline Phosphatase to treat Sepsis.

Plasma creatinine clearance, a marker for renal function, improved by 45% (median) in patients with Acute Renal Failure treated with Alkaline Phosphatase and deteriorated by 25% (median) in patients with Acute Renal Failure treated with placebo, with p values of < 0.05.


In addition, the level of glutathione-S-transferase-A1, a marker for kidney damage, decreased by 70% (median) in AP treated patients, compared to a 200% (median) increase in placebo treated patients, with p values again of < 0.05.


Fifteen patients (10 active, 5 placebo) with Acute Renal Failure were treated for 24 hours as part of a double-blind, randomized, placebo-controlled Phase IIa study in 36 Sepsis patients. The study took place in the Department of Intensive Care Medicine at the Radboud University Medical Centre, Nijmegen, The Netherlands.


Bart Wuurman, CEO of AM-Pharma commented on the positive results, saying: "We are very excited by the results in this Acute Renal Failure subgroup. It shows statistically significant and clinically relevant improvements in a condition that is very difficult to treat, has a high mortality rate and is associated with high costs through long term dialysis treatment. We now plan to explore the use of Alkaline Phosphatase in Acute Renal Failure in a separate study."


- ENDS -

Notes to editors:

About AM-Pharma www.am-pharma.com <http://www.am-pharma.com/> AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of novel compounds in the field of severe infectious diseases and inflammatory diseases.

AM-Pharma is currently conducting Phase II clinical trials on two products:

* Alkaline Phosphatase for Sepsis, Acute Renal Failure and Ulcerative Colitis. * Anti-microbial Peptide hLF1-11,for the prevention of infections in Hemopoietic Stem Cell Transplant patients.

AM Pharma is based in Bunnik, The Netherlands with a staff of 20. The company is financed by, amongst others, Forbion Capital Partners and Inventages Venture Capital. Once product safety and efficacy have been established, AM-Pharma will look for world-wide development and marketing partners for its products.

About Acute Renal Failure Hospital-acquired Acute Renal Failure occurs in as many as 4% of hospital admissions and 20% of critical care admissions. The growing incidence of hospital-acquired Acute Renal Failure is due to an increasingly aging population, an increased probability of exposure to nephrotoxic drugs in hospitals and an increasing number of surgical interventions. Depending on the severity of renal failure, mortality rates can range from 7% to as high as 80%. Of patients that do survive, between 20% and 60 % require ongoing dialysis treatment.

*** Should you be interested in downloading a white paper on AM Pharma's Alkaline Phosphatase Phase IIa trial and its application in the treatment of Acute Renal Failure, please click here - www.am-pharma.com <http://www.am-pharma.com/> or contact Justine Lamond on +44 (0)20 7268 3242 or j.lamond@northbankcommunications.com


For further information, please contact

Northbank Communica tions

Justine Lamond

Tel: +44 (0)20 7268 3242

j.lamond@northbankcommunications.com


AM Pharma

CEO Bart Wuurman

Tel: +31 (0)30 2289222

www.am-pharma.com

Justine Lamond Account Manager ---------------------------------------------

Direct line: +44 (0)20 7268 3242 Mobile: +44 (0)7919 828314 Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102

www.northbankcommunications.com

Please note our new address details are:

85 Tottenham Court Road,

London, W1T 4DU UK




'"/>




Related medicine technology :

1. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 2016  Granger Diagnostics today announced immediate availability of ... infections. This test ensures discovery of ALL bacteria, ... test requires only a simple swab of the wound ... G. Bostwick , MD, Chief Medical Officer, described ... "We are excited to make available, for the ...
(Date:5/25/2016)... , May 25, 2016 ... H1 2016"market research report that provides an overview ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/24/2016)... LONDON , May 24, 2016   ... primary endpoints demonstrating non-inferiority in overall bowel cleansing and superiority ... c leansing of ... http://photos.prnewswire.com/prnh/20130829/633895-a ) , Norgine B.V. today announced ... (1 litre PEG and ascorbate bowel preparation) versus standard 2 litre ...
Breaking Medicine Technology:
(Date:5/27/2016)... , ... May 27, 2016 , ... ... this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and ... the industry, from leading advocates, associations and industry leaders such as Bioness. ...
(Date:5/27/2016)... ... 2016 , ... Aimed at nurses and employees in the health care world, ... in the nursing and health care industry. It also provides insight to the developing ... , As the nursing industry is coming out of one of the biggest ...
(Date:5/26/2016)... , ... May 26, 2016 , ... There are many ... Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the ... percent say grilling is their favorite way to cook a hot dog, far outpacing ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia ... to its specialty academic programs. , Answering to the increasing demand for curricular ... in health law, and environmental and land use law. ,  , “The demand ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
Breaking Medicine News(10 mins):